Important Dates

09 June 2014

On-site registration opens

10 June 2014

Conference opens

Track Descriptors

Track 1: Detection and Prevention

Overview: Despite the implementation of Direct Observed Therapy Short course the incidence of Tuberculosis (TB) in South Africa continues to rise unabated and now represents the highest incidence rate world-wide. This has largely been ascribed to colliding HIV and TB epidemics and a failing health system.

Molecular epidemiological studies have clearly shown that both the drug- susceptible and drug-resistant TB epidemics are driven by on-going transmission possibly reflecting poor health seeking behaviour, congregate living and transport conditions, and doctor driven diagnostic delay. Similarly, amplification of resistance is as a result of treatment in the absence of drug-susceptibility testing (DST), use of inaccurate and slow DST, and to a lesser extend default and poor drug absorbance.

Whilst tackling the current caseload through active and passive case finding is imperative, it is also critical to prevent new cases through interrupting the transmission cycle and addressing broader issues such as poverty, overcrowding, stigma, socioeconomic factors, gender issues and HIV, which remain major drivers of the TB epidemic. Tackling operational issues within the TB programme, prophylactic therapy to high risk groups and finding an effective vaccine are also major priorities.

This session invites abstracts on the following topics:

  • Improving health seeking behaviour
  • Infection control (hospital, clinic, home and transport)
  • Interrupting transmission
  • Culture based DST
  • Rapid Diagnostics
  • Genotype vs Phenotype
  • Novel mechanisms of drug resistance
  • Impact of rapid diagnostics on treatment outcome
  • Improving laboratory turn-around-time
  • Reducing the time to entry into care
  • Retaining patients in care
  • Improved contact tracing and patient follow-up
  • Preventative therapy
  • Anti-viral therapy
  • Nutrition
  • Vaccines

Track 2: TB Treatment

Existing treatment for TB (including drug resistant TB) must be given in combination of 4-10 drugs, for at least 6 months and often for over 24 months, has limited efficacy and many serious side effects. Consequently treatment adherence is dismal and may result in some forms of TB that are currently untreatable.

After a long 'dry' period of no new drugs, several TB drug candidates are in varying stages of development and clinical trials.

Submissions for this track would include basic science, clinical research and programmatic work and may include (but are not limited to) the following:

  • Basic and translational research to identify new drugs and drug targets
  • Compound/small molecule screens
  • Drug target identification and validation
  • Drug efficacy trials
  • New drug regimens for TB
  • Drug resistance
  • Mechanisms of drug resistance

Track 3: TB Management

TB management encompasses interventions, strategies and communications aimed at improving clinical outcomes and quality of life of patients with TB.

This track will accept abstracts of operational research studies addressing:

  • Poverty and social determinants of TB disease
  • Programmatic aspects of TB prevention
  • Control and management
  • Health systems to cover all pillars of TB health system-governance
    and the role of national and local government
  • Human resources and training
  • Infrastructure
  • Supply chain management for TB drugs and access to TB drugs
  • Service delivery and quality of care
  • Monitoring and evaluation
  • Knowledge management and access to information
  • TB/HIV Integration
  • Health economics and patient costing
  • Patient and community education
  • Information
  • Advocacy
  • Communication and social
  • Mobilisation around TB prevention and treatment

Conference Updates


Conference Presentations


Promotional Material

Please click here to view,share and download our conference material.

Facebook Feeds

Twitter Feeds